Details of the Board & Leadership

Board of Directors
Senior Management

Board of Directors

Summarized biographies of the Directors and details of their roles, including the principal activities performed by the Directors outside the Company, are set out below.

Stark Thompson, PhD - Non-executive Chairman

Dr. Thompson has nearly five decades of corporate leadership and business management experience, dating back to when he joined the DuPont Company in 1967 where he spent more than 20 years. From 1988 until 2000, Dr. Thompson served as President, CEO and board member of Life Technologies, Inc. (LTI; NASDAQ: LTEK). Dr. Thompson has served on and led various boards of directors, including for companies such as Gene Logic, Inc. and Luminex Corporation (NASDAQ: LMNX). Dr. Thompson received his BS degree from Muskingum University, and his MSc and PhD in Physiological Chemistry from Ohio State University.
Doug Doerfler - President and Chief Executive Officer

Mr. Doerfler has over 35 years’ experience in the discovery, development, commercialization and international financing of biotechnology products and companies. He was a founder of MaxCyte in July 1998. Previously, Mr. Doerfler was President, Chief Executive Officer and a director of Immunicon Corporation, a cell-based therapy and diagnostics company. Mr. Doerfler also held various executive positions with Life Technologies, Inc. that included leading its global businesses, mergers and acquisitions and its IPO. Mr. Doerfler plays an active role as a life sciences industry advocate, serving as Chair Emeritus of the Maryland Tech Council and on the Executive Committees of the Alliance for Regenerative Medicine and the Biotechnology Innovation Organization. Mr. Doerfler received his BS in finance from the University of Baltimore School of Business, and holds a certificate in Industrial Relations.
Ron Holtz – Chief Financial Officer

Mr. Holtz serves as MaxCyte’s Chief Financial Officer (“CFO”), having joined the Company in 2005. Previously, he has been CFO of both public and private companies and has raised more than $100 million in debt and equity capital. He also has previous experience with Ernst & Young LLP’s Financial Advisory Services Group. He earned an MBA in finance from the University of Maryland, a BS in mathematics from the University of Wisconsin and is a Certified Public Accountant.
Will Brooke – Non-executive Director

Mr. Brooke is Executive Vice President and a director of Harbert Management Corporation (“HMC”), which he co-founded in 1993. With approximately $4 billion under management, HMC sponsors and co-invests in alternative asset strategies worldwide. Mr. Brooke organized and led one of HMC’s investment strategies, Harbert Venture Partners, for over a decade. He has been advising and investing in early stage and growth companies for more than 20 years, and served on the boards of numerous pharmaceuticals and medical equipment companies (e.g., Aldagen Corporation, Atherotech, Inc. and Emageon Corporation). Mr. Brooke has also served as HMC’s General Counsel, its Chief Operating Officer, and as chairman of its Real Estate Services subsidiary. Prior to joining HMC, Mr. Brooke practiced law for a decade. Mr. Brooke holds a JD and a BS, both from the University of Alabama.
Stan Erck – Non-executive Director

Mr. Erck, President and CEO, and director of Novavax Corporation, applies his 25 years of management experience in the healthcare and biotechnology industry (Baxter International, Procept, Integrated Genetics, and Iomai) to shepherd the development and commercialization of Novavax Technology. In addition to successfully negotiating major alliances with pharmaceutical and biotechnology companies and bringing products into clinical trials, as CEO he has managed the process of developing companies from private funding through to IPO. Mr. Erck received his B.S. from the University of Illinois and an M.B.A. from the University of Chicago.
Art Mandell – Non-executive Director

Mr. Mandell is a senior executive in the healthcare industry with over 30 years of experience running companies, executing large corporate and business development deals in both the pharmaceutical and biotechnology sectors, and developing and commercializing a number of products. Mr. Mandell served as President and Chief Operating Officer of Prestwick Pharmaceuticals, Inc. Prior to Prestwick, Mr. Mandell was President, Chief Executive Officer, and a director of Cellective Therapeutics, Inc., which was acquired by Astra Zeneca/MedImmune under his leadership. Before Cellective, Mr. Mandell served as President, Chief Executive Officer, and director of Stemron Corporation, and as Senior Vice President and Chief Business Officer of Human Genome Sciences, Inc. Mr. Mandell began his healthcare career at Syntex Pharmaceutical Corporation.
John Johnston – Non-executive Director

Mr. Johnston is currently a Non-Executive director of Flowgroup plc and Midatech Pharma plc, and Non-Executive chairman of Constellation Healthcare Technologies Inc. Previously, he has held roles at Nomura Code and Seymour Pierce from 2008 to 2011. In 2003, Mr. Johnston founded Revera Asset Management, where he oversaw an investment trust, a unit trust and a hedge fund, which he ran until 2007. From 1992 to 1997, Mr. Johnston was Head of Small Companies at Scottish Amicable, before spending a year at Ivory and Sime. He joined Legg Mason Investors for three years as director of Small Companies Technology and Venture Capital Trusts, from 2000 to 2003, having previously spent two years as Head of Small Companies with Murray Johnstone. Mr. Johnston began his investment career at the Royal Bank of Scotland.
Back to Top

Senior Management

Short biographies of the Company's senior management and details of their roles are set out below:

Madhusudan V. Peshwa, PhD, Chief Scientific Officer, Executive Vice President, Cellular Therapies

Dr. Peshwa currently serves as Chief Scientific Officer at MaxCyte. Before joining the Company in 2005, he was Limited Partner and Executive Vice President for Research and Development at NewNeural, LLC, a start-up company focused on small molecule drugs and ex vivo stem cell therapies for CNS diseases. Prior to that, Dr. Peshwa served as Vice President of Manufacturing and as Vice President of Process Sciences at Dendreon Corporation (NASDAQ: DNDN), where he was responsible for development, characterization and manufacture of an autologous dendritic cell vaccine product from concept to late Phase III pivotal studies and design of commercial manufacturing infrastructure; scale-up and production of recombinant protein using baculovirus transient transfection system at 2000L bioreactor scale; and CE mark, 510(k), IDE and PMA for a Cell Separation technology platform. His expertise is in the areas of ideation, design, development, characterization, scale-up and commercial development of recombinant proteins; engineered cell and tissue products; and medical devices. Dr. Peshwa obtained his PhD in chemical engineering from the University of Minnesota and his BTech in chemical engineering from the Indian Institute of Technology, Kanpur, India. He is a co-author on over 30 scientific publications and is a co-inventor on over 10 patent applications.
Debra K. Bowes, Executive Vice President, Business and Strategic Development

Ms. Bowes has more than 25 years’ experience in corporate strategy, licensing and in the creation of partnerships to advance the development and commercialization of biopharmaceutical products, with a main emphasis in oncology. Before joining MaxCyte in 2016, Ms. Bowes was interim President and Chief Executive Officer of CapGenesis Pharma, in Bethesda, MD. Previously, she served as President and Founder of Chevy Chase BioPartners, LLC, a strategic planning consultancy, as well as in leadership positions at CBLI Pharmaceuticals, MedImmune, Amylin Pharmaceuticals, Pfizer, Ligand Pharmaceuticals, Centocor and Hybritech. She also has served as national president of Women In Bio. Ms. Bowes received a Master’s from Johns Hopkins University, and a BS in cell biology from the University of Cincinnati.
Thomas M. Ross, Executive Vice President, Global Sales

Mr. Ross serves as MaxCyte's Executive Vice President of Global Sales, having joined the Company in 2014. Mr. Ross has extensive experience in all elements of commercial operations and has over 25 years of successful sales and marketing leadership in the Life Science and Clinical Diagnostics markets. Most recently, Mr. Ross was Senior Vice President of Commercial Operations at OpGen®. Mr. Ross also served as Chief Commercial Officer at Predictive BioScience and Vice President of North America Medical Diagnostics Sales at Qiagen/Digene Corporation. Prior to working at Digene Corporation, Mr. Ross held several senior leadership roles in Manufacturing Operations at LTI and Cambrex. Mr. Ross has a Bachelor’s of Business Administration from The Citadel.
James Brady, Vice President, Technical Applications and Customer Support

Dr. Brady is Vice President of Technical Applications and Customer Support at MaxCyte, Inc. Prior to joining MaxCyte in 2004, Dr. Brady was a Senior Scientist at Genetic Therapy, Inc., a Novartis subsidiary, where he worked on lentiviral-based gene therapy treatments for ocular disorders. Previously, he worked at MetaMorphix, Inc. as a Group Leader in the Company’s Transgenic Livestock program, and was a postdoctoral fellow at the National Eye Institute of the National Institutes of Health. Dr. Brady received a Bachelor of Science degree in biology from the College of William and Mary, a Ph.D. in genetics from Indiana University and an MBA from Johns Hopkins University.
Markus J. Hunkeler, Vice President, Marketing

Mr. Hunkeler joined MaxCyte in 2016 as Vice President of Marketing. With over 25 years in life science company leadership positions, Mr. Hunkeler brings a wide variety of product and marketing experiences to MaxCyte. Most recently Mr. Hunkeler managed international sales for ATCC. Prior to that, he was Director of Product Development at Life Technologies Corporation, Senior Director of Marketing at BioReliance and Director of Marketing at Lonza. Mr. Hunkeler has Bachelor and Master of Science degrees in biochemistry and an MBA from the University of Maryland.
Back to Top


H. Kim Lyerly, M.D., FACS
Duke University School of Medicine

Dr. Lyerly serves as a Professor in the Department of Surgery, Associate Professor in the Department of Pathology, and Assistant Professor in the Department of Immunology at Duke University Medical Center. He serves as the George Barth Geller Professor for Research in Cancer and is an experienced surgical oncologist. He is also a Co-Leader of the Breast and Ovarian Oncology Research Program of Duke and Principal Investigator of the Duke Specialized Program in Research Excellence (SPORE) grant in breast cancer. He has been Director of the Duke Comprehensive Cancer Center since 2003. He serves as a Consultant and Advisory Board Member to the National Cancer Institute and various biotechnology and pharmaceutical companies. He co-directs the NCI sponsored workshop of cancer clinical trials and is the scientific chair of the Southwest Oncology Group Molecular Therapeutics Committee. He serves on the Editorial Boards of several peer-reviewed journals, including Cancer Investigation, Clinical Cancer Research, and Cancer Gene Therapy. He has published nearly 200 papers and book chapters, and has edited or co-edited 7 books. He is on the editorial board of several publications, including Surgery, Annals of Surgery, and Clinical Cancer Research. He was trained in Surgery at Duke University Medical Center, from 1984 to 1985, and 1987 to 1990 and in Research at Duke University Medical Center, 1985 to 1987. Dr. Lyerly received his medical degree from the University of California, Los Angeles.
David E. Weng, M.D., Ph.D.
Dr. Weng is a board-certified medical oncologist, with a professional career that encompasses both clinical activity and research in academic and community medicine, and extensive experience for the development of new diagnostics and therapies within of the biotechnology industry. Currently, Dr. Weng has clinical responsibilities for the care of patients with hematologic and solid tumor malignancies, clinical trials research, health care outcomes, quality management, and cost of care analysis. He was previously the chief medical officer for TetraLogic Pharmaceuticals and also previously worked at MedImmune, before its acquisition by Astra Zeneca. Dr. Weng was on staff at the Cleveland Clinic and was vice chair of its Institutional Review Board. He has been an advisor and investigator for development of new therapeutic approaches including target selection, preclinical drug development, chemotherapy cytotoxic agents, hormonal therapies, small molecule agents, monoclonal antibodies, cellular therapies, diagnostics, and imaging. Dr. Weng has been involved as an investigator in over 40 oncology studies during his research career. He has over 70 publications and abstracts in the fields of developmental biology, cancer biology, immunology, and clinical research. Dr. Weng is board-certified in medical oncology and internal medicine. He earned his Bachelor’s degree in biochemical sciences from Harvard University and medical and doctorate degrees from the Johns Hopkins University School of Medicine. He completed his internal medicine residency training at the Johns Hopkins Hospital, followed by fellowship training in medical oncology at the National Cancer Institute.
Back to Top